Trial Profile
Phase II Study of Sorafenib/Avastin as Salvage Therapy in Patients With Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
- Indications Colon cancer; Rectal cancer
- Focus Biomarker; Therapeutic Use
- 07 Aug 2017 Status changed from active, no longer recruiting to completed.
- 06 Feb 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Jun 2012 Actual end date Jan 2010 added as reported by ClinicalTrials.gov.